Dolutegravir for the treatment of adult patients with HIV-1 infection.
Dolutegravir, is a second generation integrase inhibitor that had recently received United States Food and Drug Administration and European Commission approval for the treatment of adult patients with HIV-1 infection. Dolutegravir provides distinct advantages compared with first generation integrase inhibitors. Unlike raltegravir, dolutegravir can be given once daily for patients who are antiretroviral treatment naïve. Once-a-day dolutegravir dosing also does not require a pharmacokinetic booster like elvitegravir which minimizes the drug-drug interaction potential of dolutegravir. In Phase III clinical trials, dolutegravir-containing regimens have demonstrated either non-inferiority or superiority to current first line agents such as raltegravir, darunavir/ritonavir, and efavirenz containing regimens. Moreover, dolutegravir may be effective for patients with a history of raltegravir and/or elvitegravir resistance. Dolutegravir will likely play a major role in the management of patients with HIV-1 infection, and will be aided when coformulation with abacavir/lamivudine as a single pill, once-daily regimen is available.
Department of Pharmacy, New York Methodist Hospital, 506 6th Street, Brooklyn, NY 11215, USA.
Gary
G
Wu
Teena
T
Abraham
Nasser
N
Saad
D000328:Adult; D002986:Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019427:HIV Integrase / Q000378:metabolism*; D019428:HIV Integrase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006575:Heterocyclic Compounds, 3-Ring / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000493:pharmacokinetics / Q000627:therapeutic use; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones / Q000493:pharmacokinetics / Q000627:therapeutic use; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D000099226:Dolutegravir; D000099227:Abacavir
D015224:Dideoxynucleosides; D004338:Drug Combinations; D019427:HIV Integrase; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D019259:Lamivudine; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; D000099226:Dolutegravir; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir; C509700:elvitegravir